March 16, 2021 5:08pm
Waiting for the Fed, whatever the Fed chair says, it will move markets; just a question of direction
Pre-open indication results: 6 HITs and 2 MISS
Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence
The Dow closed DOWN -127.51 points (-0.39%); the S&P closed DOWN -6.23 points (-0.16%) while the Nasdaq closed UP +11.86 points (+0.09%)
Henry’omics:
The Dow fell from its record high and snapped seven-day winning streak on Tuesday, the S&P fell after setting an all-time high for three (3) consecutive sessions as the Nasdaq barely performed but, did stay up.
Traders will get more guidance from the Federal Reserve on rates and inflation on Wednesday.
Data Docket: February retail sales fell by more than expected, down 3%, data released Tuesday showed, reflecting in part a month marked by severe weather across the US. However, January’s retail sales figures were revised upward to a 7.6% jump from a 5.3% increase, so the markets largely ignored the number.
RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: whack-a-mole; It’s more than an arcade game and more about randomness” … https://www.regmedinvestors.com/articles/11816
Pre-open indication results: 5 HITs <Solid Biosciences (SLDB -$3.08), Applied Genetic Technologies (AGTC -$0.11), Athersys (ATHX +$0.01), CRISPR Therapeutics (CRSP -$3.03), Editas Medicine (EDIT -$2.30) and 3 MISS < SELL: Biostage (BSTG +$0.02 with 210 shares), Chinook Therapeutics (KDNY -$1.34), Pluristem (PSTI -$0.21);
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …
- Tuesday opened negative at 11/22, 1 flat and 1 acquired, stayed negative at the mid-day to 11231 and 1 acquired, closing negative at 4/30 and 1 acquired;
There are clear winners and losers
Jumping with share pricing momentum:
- ReNeuron (RENE.L), AxoGen (AXGN), Cellectis SA (CLLS), Biostage (BSTG) to name 4 of the 4 inclining of the 35 covered
Hammered in today’s market:
- CRISPR Therapeutics (CRSP), Solid Biosciences (SLDB), Fate Therapeutics (FATE), Sage Therapeutics (SAGE), Alnylam Pharmaceuticals (ALNY) to name 5 of the 30 declining of the 35 covered
Key metrics:
- Sector volume was LOW with 1 of the 4-upside having higher than the 3-month average volume with the volume of 3 of 30-downside having higher than the 3-month average volume;
- Tuesday’s percentage (%) of the 4-upside were +0.92% (CLLS) to +8.82% (RENE.L) while the 30-downside ranges from -0.01% (RARE) to -32.39% (SLDB);
Tuesday’s (4 of 4) incline
- ReNeuron (RENE.L +$9.00 after Monday’s +$1.00);
- AxoGen (AXGN +$0.64 after Monday’s -$0.24);
- Cellectis SA (CLLS +$0.20)
- Biostage (BSTG +$0.02 after Monday’s +$0.02)
Tuesday’s (10 of 30) decliners:
- Solid Biosciences (SLDB -$3.08 after Monday’s -$0.01);
- Fate Therapeutics (FATE -$3.04 after Monday’s -$1.22);
- CRISPR Therapeutics (CRSP -$3.03 after Monday’s +$2.99);
- Sage Therapeutics (SAGE -$2.84);
- Intellia Therapeutics (NTLA -$2.51 after Monday’s +$2.54);
- Alnylam Pharmaceuticals (ALNY -$2.34 after Monday’s +$3.92);
- Editas Medicine (EDIT -$2.30 after Monday’s +$1.69);
- Vericel (VCEL -$1.95);
- Global Blood Therapeutics (GBT -$1.78 after Monday’s +$1.99);
- Chinook Therapeutics (KDNY -$1.34 after Monday’s -$0.08);
Closing Flat: 1 - Stemline Therapeutics (STML – acquired)
Sentiment and COVID-19 infections:
- The U.S. is recording at least 55,300 new Covid-19 cases and at least 1,300 virus-related deaths each day, based on a seven (7) day average <calculated by CNBC using Johns Hopkins University data>.
Infection cases <Million>: never to forget …
- Tuesday 29.50 M cases,
- Tuesday’s death rate totaled 535,994 <Johns Hopkins University>
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday, the IBB closed up +0.02% and XBI closed down -1.57%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was down -0.24 points or -1.20% at 19.79
Upside volume: low
- Tuesday: 1 out of the 4-upside had higher than the 3-month average volume;
Downside volume: low
- Tuesday: 3 out of the 30-downside had higher than the 3-month average volume;
Percentage (%) movement/range statistics: % and pricing drop
- Tuesday’s percentage (%) of the 4-upside were +0.92% (CLLS) to +8.82% (RENE.L) while the 30-downside ranges from -0.01% (RARE) to -32.39% (SLDB);
March, the 3rd month of Q1/21:
Tuesday closed negative with 4 advancers, 30 decliners and 1 acquired
The BOTTOM LINE: What has changed - sustainability is the real issue in “this” market!
Markets are scary, frightening investors – volatilities basis is pure speculation i.e., gambling.
NOT for me - I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run.
As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice has been … trim and skim … if one can!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
